The majority of patients with acute promyelocytic leukemia (APL) possess either a bcr1 or a bcr3 type fusion between PML and RAR␣ genes. The junction sequences may possibly be a target for immune response and influence susceptibility to the disease. In this case, HLA class I allele frequencies would be different between bcr1 and bcr3 patients. To test this hypothesis, we typed 102 APL patients for HLA-A, -B and -Cw alleles. The A*1, A*30, B*51, B*41, Cw*0602, and Cw*1701 alleles showed a different distribution between bcr1 and bcr3 patients, but in no case was this statistically significant after correction for the number of comparisons or was confirmed in an independent panel. Moreover, no difference was detected between bcr1 and bcr3 when HLA alleles were grouped according to their peptide binding specificities. Comparing HLA frequencies, clinical features at diagnosis and clinical outcome of the 64 patients homogeneously treated with all-trans retinoic acid and idarubicin (AIDA protocol) we observed a statistically significant association between HLA-B*13 and risk of relapse by univariate and multivariate regression analysis. Should this finding be confirmed in larger future studies, this observation would be of outmost importance in identifying patients at high risk of relapse in which more aggressive consolidation therapies should be used. Leukemia (2000) 14, 393-398.
Introduction
Unlike other leukemias, where an association with HLA has been intensively sought, [1] [2] [3] no HLA typing data are available for acute promyelocytic leukemia (APL).
APL is characterized by a t(15;17) translocation, involving the retinoic acid receptor ␣ (RAR␣) gene on chromosome 17 and the PML (promyelocytic) gene on chromosome 15 . RAR␣ belongs to the superfamily of nuclear hormone receptors while PML encodes a member of the zinc RING finger family of nuclear proteins. The translocation generates the PML/RAR␣ chimeric gene which is expressed as a fusion product containing large portions of both PML and RAR proteins. The fusion protein acts as a transcriptional repressor that interferes with the normal pathway of gene expression involving the RARs/RXR (retinoid X receptor) complex. 4 Within the PML gene, DNA breaks cluster in three different regions named bcr1, bcr2 and bcr3. Bcr1 and bcr3 are the most frequently involved in APL (92-95% of cases) and produce a unique PML/RAR␣ fusion product, whereas bcr2 leads to several different products because of alternative splicing. 5 The relevance of an HLA association study in APL stems from the following considerations: the junction regions of bcr1 and bcr3 regions code for distinct amino acid sequences. They can be considered as immunologically 'non-self' in that the peptides crossing the fusion point cannot be generated from
Correspondence: E Bolognesi, Dipartimento di Scienze Mediche, Via Solaroli 17, 28100 Novara, Italy; Fax: 39 0321 620421 Received 30 July 1999; accepted 8 November 1999 the normal gene products (Figure 1 ). Therefore they could act as bcr1-and bcr3-specific tumor-associated antigens and could induce protective anti-APL immunity. The possibility that fusion proteins deriving from chromosomal translocations represent a candidate target for an HLA restricted T cellmediated antitumor response has been already suggested for CML patients. 6, 7 Since APL cells do not express HLA class II molecules, 8, 9 it is more likely that any direct killing of such cells by cytotoxic T cells involves class I molecules and CD8
+ T cell recognition. Thus, HLA alleles coding for molecules that bind bcr1 or bcr3 fusion peptides should be under-represented among the patients of either bcr1 or bcr3 type. If the immune response does not prevent the disease onset but it influences its clinical features, HLA class I allele frequencies could vary according to clinical parameters.
Accordingly, the aims of the present study were three-fold: (1) to collect the first data on HLA association in APL, by comparing the HLA frequencies in Italian APL patients with those of an ethnically matched control population; (2) to check whether there is any differential HLA profile in the two types of rearrangements that could underlie a different immunemodulated susceptibility; and (3) to test for any correlation between HLA, type of rearrangement and selected clinical parameters.
Materials and methods

Patients
One hundred and two APL patients were included in this study. The patient samples were diagnosed and provided by the clinical centers belonging to the Italian Cooperative Group GIMEMA over a period of time ranging from 1988 to 1997. All the patients were Italian. Approximately 43% of the patients were contributed by centers located in northern Italy, 38% in the center, 16% in the south and 3% in Sardinia. Diagnosis of APL was based on French-American-British guidelines. 10 All patients presented PML/RAR␣ rearrangements with or without a cytogenetically detectable t (15;17) . At diagnosis, patients mean age was 39.4 (±15.7) years and white blood cell (WBC) count was 12.5 ± 22.3 × 10 9 /l. Disseminate intravascular coagulopathy (DIC) and hemorrhages were present in 76.1% and 60.5% of cases. Bcr1 and bcr3 PML/RAR␣ isoforms were in 66 and 36 patients, respectively. Sixty-four out of 102 patients were treated by the AIDA protocol in which ATRA is combined with idarubicin chemotherapy. 11 In this latter group of patients, after a minimum follow-up of 1.5 years, 46/64 patients persisted in continuous complete remission (CCR) while 18 patients presented an overt relapse of disease.
Figure 1
The PML-RAR␣ gene fusion involving chromosome 15 and 17. Arrows indicate the possible breakpoints generating bcr1, bcr2 and bcr3 type fusions. In bcr1 fusion protein, exon 6 of PML fuses with exon 3 of RAR␣, allowing the generation of a 'new' alanine residue (in bold). In bcr3, the fusion protein is originated from the region 5Ј to PML exon 3 and the region 3Ј to RAR␣ exon 3. Also in this case, a new alanine residue is formed. The amino acid sequences of the bcr1 and bcr3 junction regions are indicated.
Controls
Controls included 101 cadaver kidney donors and 200 cord blood units for which genomic HLA-A, B typing was performed in the Transplant Center of Turin 12, 13 in Piedmont (north-west Italy). This population absorbed several migration waves from other Italian regions. The control panel, therefore, though composed predominantly (60%) by people of northern Italian origin, also includes a large (40%) component from the center and the south. HLA-A, B frequencies in this panel were very similar to those reported for 159 311 serologically typed Italian bone marrow donors whose regional composition was 59% from northern Italian regions, 35% from the center and south, and 5% from Sardinia.
14 Thus the control panel can be considered as representative of the whole Italian population and reasonably corresponds to the regional distribution of the patients' panel.
The control HLA-C frequencies were taken from those genomically typed in a limited sample from the Italian population (n = 101) during the XII Histocompatibility Workshop. 15 
PML-RAR␣ characterization
In older samples (n = 55), the fusion type was determined on genomic DNA by Southern blot analysis. 16 In more recently collected patient samples (n = 47), the hybrid transcripts were evaluated on cDNA by RT-PCR with a nested polymease chain reaction specific for bcr1, bcr2 and bcr3 fusion types. 17 High molecular weight DNA was obtained from isolated mononuclear cells following proteinase-K digestion and phenol-chloroform extraction. Total RNA was extracted from cells cryopreserved in guanidine isothiocyanate according to the method of Chomczynsky and Sacchi. 18 cDNA was obtained by retrotranscription of 1 g of RNA by the Moloney leukemia virus derived reverse transcriptase (Gibco BRL, Italia), according to the manufacturer's instructions.
HLA class I typing
Class I alleles were typed either on genomic DNA (55 patients) or on cDNA (47 patients).
Genomic DNA from 39 bcr1 and 16 bcr3 patients was typed for HLA-A, -B and -Cw alleles by the SSP-ARMS-PCR (sequence specific primer-amplification refractory mutations system-polymerase chain reaction), using the 12th International Histocompatibility Workshop typing kit. It allows a medium to low resolution for all loci. 19 cDNA of a further 27 bcr1 and 20 bcr3 patients was typed for HLA-A and -B alleles by a PCR-SSOP method, 20, 21 that allows assignment of all the HLA class I serological specificities and a nearly complete assignment of molecular subtypes. 21 bcr1 and 20 bcr3 patients, included in the same cDNA panel, were also typed for Cw*0602 and Cw*1701. Cw*1701 was typed by the same SSP-ARMS-PCR approach utilized for genomic DNA typing: a 229 bp fragment was obtained after cDNA amplification. A specific approach was designed for Cw*0602: cDNA was amplified by primers 5ЈTACGGTCGACGATTCTTCCCAGACGCCGAGATGCGG3Ј (forward) and 5ЈCATGGGATCCCAGGCAGCTGTCTC-AGGCTTTACAAG3Ј (reverse) that coamplify HLA-B and C cDNA fragments. 22 PCR products were then hybridized with the SSO AGCCCCGGGCGCCGT corresponding to the amino acid position 46-51. 23 
Statistical analysis
Reported frequencies for the various alleles refer to the number of individuals carrying a given allele (phenotypic frequency).
For categorical variables, significance of association was evaluated by X 2 (Yates correction) or, when this is requested from the small number of expected cases, by two-tailed Fisher's exact test. For continuous variables (age and WBC count at presentation), the association was analyzed by the non-parametric Mann-Whitney test. The P values shown in the Tables were not corrected for multiple comparisons. A multivariate analysis was performed to evaluate the influence of all variables simultaneously upon the clinical outcome (CCR or relapse) using the logistic regression model; in the full model all the variables are considered together, in the reduced model non-significantly-associated variables are excluded by a stepwise procedure.
Results
HLA-A, -B, -Cw frequencies in APL patients
Considering the whole patient panel, regardless of the fusion type, the frequency of HLA-A, -B, -Cw tested alleles was similar to that reported for the Italian population (Tables 1 and 2 ). The only statistically significant difference concerned B*52 (P = 0.045) but it did not withstand correction for the number of comparisons. Genotype frequencies in the patients were in accordance with Hardy Weinberg equilibrium.
When considering the patients subdivided according to the bcr1 and bcr3 fusion type, borderline deviations between the two types were seen (Table 1) for A*1, A*30, B*51 that were decreased in bcr3 vs bcr1 patients (A*1: 12.5% vs 30%, P = 0.057; A*30: 2.8% vs 17.2%, P = 0.051; B*51: 5.6% vs 21.9%, P = 0.064) and for B*4101 that was decreased in bcr1 (1.6% vs 11.1%, P = 0.055). The observed differences were Table 1 HLA-A and -B phenotypic frequencies (%) in bcr1 and bcr3 APL patients and in healthy controls
HLA allele APL (all) bcr1 bcr3 Controls HLA allele APL (all) bcr1 bcr3 Controls n = 100 n = 64 n = 36 n = 301 n = 100 n = 64 n = 36 n = 301 Leukemia far from significant when P was corrected for the number of comparisons.
Of the 15 HLA Cw alleles typed on 55 APL genomic DNA samples (Table 2) , Cw*0602 (P = 0.0274) and Cw*1701 (P = 0.0116) showed a statistically significant difference between bcr1 and bcr3. To confirm these results, an independent set of 41 APL cDNAs was typed for these two alleles. No significant difference in bcr1 and bcr3 types was seen either in this second panel (Table 2 , bottom) or in the combined data set.
HLA-A and -B typing data were also evaluated according to so-called HLA-supertype groups (Table 3) . Each HLA-supertype group consists of HLA class I alleles that share peptide binding motifs and thus possibly represents a functionally differentiated family. 24 Four supertypes have been described: HLA-A2 including nine HLA-A allelic molecules, HLA-A3 including five -A alleles, HLA-B7 with 17 -B alleles and HLA-B44 including eight -B alleles. Also in this analysis no significant difference between bcr1 and bcr3 was found.
Correlation with clinical features
HLA frequencies were compared in patients subdivided according to age and WCB count at diagnosis and to the presence or absence of DIC or hemorrhagic syndrome. Some correlations were found, with generally modest statistical significance (Table 4) . None of them was dependent on the fusion type. Correlation of HLA with response to therapy was tested Table 3 HLA supertype group phenotypic frequencies (%) in bcr1 and bcr3 APL patients and healthy controls HLA APL (total) Bcr1 Bcr3 Controls supertype a n = 100 n = 64 n = 36 n = 301 in the 64 patients homogeneously treated with the AIDA protocol (all-trans retinoic acid combined with anthracyclinebased chemotherapy). A significant increase of HLA-B*13 (33.3% vs 4.3%, P = 0.0046) with a relative risk of 11.0 (confidence limits 1.96-61.61) was found in relapsed patients (n = 18) as compared to patients maintaining a CCR (n = 46). Also this correlation was independent of the type of rearrangement (Table 5) . A multivariate analysis including B*13, type of rearrangement, age and WBC count at onset, DIC and hemorrhage was performed using the logistic regression model on the 54 patients for which information for all the considered variables was available. The only significantly associated variable was B*13 with P = 0.008 in the full model and P = 0.006 in the reduced model.
Discussion
The present study failed to detect any evidence of an HLAclass I modulated mechanism in susceptibility to APL. The most likely interpretation is that none of the APL fusion peptides binds to HLA class I with an affinity sufficient to be presented to cytotoxic T cells. This interpretation is in line with the observation that no known HLA binding motifs are present in the bcr1 and bcr3 PML-RAR␣ fusion peptides. 25 In fact, no direct binding to HLA-A*0201, B*5101 and B*4402 molecules was found for any of the nonapeptides possibly generated from the APL bcr1 and bcr3 fusion region. 26, 27 Another possible explanation comes from the recent observation by Zheng et al 28 that mutations involving PML downregulate MHC expression with a dominant-negative mechanism acting on transcription of the genes involved in antigen processing. According to these authors, malfunction of PML consequent to its fusion with RAR␣ might be the reason why TAP-1, TAP-2, LMP-2, LMP-7 and cell surface MHC class I are barely detectable on the NB4 APL cell line. If this is a common feature of APL cells, it may hinder host immune surveillance.
The present study also failed to show any bcr1-or bcr3-specific HLA correlation of several clinical parameters such as age and WBC counts at diagnosis and vascular complications.
Concerning correlations among HLA allele frequencies and patients' clinical features and outcome, the most interesting observation is that HLA-B*13 was significantly increased in relapsed APL patients. This finding was further confirmed by a multivariate analysis which demonstrated that B*13 was the only parameter influencing the risk of relapse (P = 0.006). In our opinion, although derived from a retrospective evaluation, this finding is clinically relevant in order to identify poor prognostic factors with the currently adopted therapy programs for APL patients. In fact, although prognosis of APL patients has dramatically changed with the introduction of therapeutic programs in which all-trans retinoic acid (ATRA) is combined with anthracycline-based chemotherapy, early death during induction and occurrence of relapse still represent the major obstacles to final cure of this disease. The biological meaning of this finding is not clear. Likely, HLA-B*13 may be a marker in linkage disequilibrium with another genetic factor that can influence response to therapy.
In conclusion, our present data did not show any evidence suggesting a possible HLA-class I related mechanism in suceptibility to APL. However, the statistically significant correlation between the presence of HLA-B*13 and relapse risk is a novel and clinically relevant observation. This finding, if confirmed in larger future prospective studies, might be useful to identify patients at high risk of relapse that should be treated with more aggressive consolidation therapies.
